Bendamustine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Bendamustine
- Bendamustine: From Follicular Lymphoma and Other B-Cell Malignancies to Mantle Cell Lymphoma
Bendamustine: From Follicular Lymphoma and Other B-Cell Malignancies to Mantle Cell Lymphoma
One-Sentence Summary
Bendamustine is an alkylating chemotherapy agent originally used for B-cell malignancies such as follicular lymphoma, mature B-cell neoplasms, acute lymphoblastic leukaemia and Richter syndrome. The TxGNN model predicts it may be effective for Mantle Cell Lymphoma (MCL). Currently 42 clinical trials and 20 publications support this direction, including several completed Phase 3 randomised trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Follicular lymphoma, mature B-cell neoplasms, acute lymphoblastic leukaemia, Richter syndrome (the Singapore registration records contain no indication text) |
| Predicted New Indication | Mantle cell lymphoma |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Bendamustine is known as an alkylating agent with some nucleoside-analogue-like properties. It damages DNA and is active across B-cell malignancies.
Mantle cell lymphoma is a mature B-cell neoplasm that is closely related to bendamustine's original indications (follicular lymphoma and other mature B-cell neoplasms). Because the disease biology is similar, the cytotoxic mechanism is expected to carry over.
Randomised Phase 3 trials already use bendamustine plus rituximab (BR) as a first-line backbone in MCL. It has been compared directly with R-CHOP, and BTK inhibitors have been added on top of it. This supports the model's prediction.
Clinical Trial Evidence
The 10 most relevant of the 42 registered trials are listed below.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00991211 | Phase 3 | Completed | 549 | First-line BR vs R-CHOP in advanced indolent lymphoma and MCL, testing non-inferiority for progression-free survival |
| NCT00877006 | Phase 3 | Completed | 447 | BRIGHT study: BR vs R-CVP/R-CHOP in first-line indolent NHL or MCL, primary endpoint complete response rate |
| NCT01776840 | Phase 3 | Completed | 523 | Ibrutinib vs placebo added to BR in newly diagnosed MCL, patients aged 65 or older |
| NCT02972840 | Phase 3 | Active, not recruiting | 635 | Acalabrutinib vs placebo added to BR in previously untreated MCL |
| NCT06363994 | Phase 3 | Recruiting | 476 | Orelabrutinib plus BR vs placebo plus BR in treatment-naïve MCL |
| NCT04115631 | Phase 2 | Active, not recruiting | 360 | Three-arm comparison of BR plus cytarabine, with or without acalabrutinib, in untreated MCL (age 70 or younger) |
| NCT00891839 | Phase 2 | Completed | 45 | Efficacy and safety of BR in relapsed/refractory MCL |
| NCT00992134 | Phase 2 | Completed | 41 | Rituximab-bendamustine-cytarabine (R-BAC) in MCL patients not eligible for intensive therapy or transplant |
| NCT03834688 | Phase 2 | Completed | 33 | Venetoclax plus BR in untreated MCL over 60 years of age |
| NCT01737177 | Phase 2 | Completed | 42 | Bendamustine, lenalidomide and rituximab as second-line therapy in first relapsed/refractory MCL |
Literature Evidence
The 10 most relevant of the 20 publications are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23433739 | 2013 | RCT | Lancet | Open-label Phase 3 non-inferiority trial of BR vs R-CHOP as first-line treatment in indolent lymphoma and MCL |
| 24591201 | 2014 | RCT | Blood | BRIGHT study: randomised Phase 3 non-inferiority comparison of BR vs R-CHOP/R-CVP in treatment-naïve indolent NHL or MCL |
| 30811293 | 2019 | RCT | J Clin Oncol | BRIGHT 5-year follow-up with long-term efficacy and safety data |
| 35657079 | 2022 | RCT | N Engl J Med | Ibrutinib added to BR followed by rituximab maintenance may benefit older patients with untreated MCL |
| 40311141 | 2025 | RCT | J Clin Oncol | Acalabrutinib plus BR in untreated MCL. Ibrutinib plus BR had extended progression-free survival but not overall survival, likely because of toxicity, and acalabrutinib may be less toxic |
| 41052510 | 2025 | RCT | Lancet | ENRICH Phase 2/3 trial: chemotherapy-free ibrutinib-rituximab vs standard immunochemotherapy (R-CHOP or BR) in patients aged 60 or older |
| 32985902 | 2021 | RCT (design) | Future Oncol | Phase 3 design of zanubrutinib plus rituximab vs BR in transplant-ineligible untreated MCL |
| 40975105 | 2025 | Phase 2 | Lancet Haematol | Venetoclax after rituximab-bendamustine-cytarabine in older patients with high-risk MCL. R-BAC is described as a standard initial treatment for older, fit patients |
| 32126141 | 2020 | Cohort | Blood Adv | Pooled analysis of rituximab/bendamustine followed by rituximab/high-dose cytarabine before transplant in transplant-eligible MCL |
| 41132246 | 2025 | Guideline | HemaSphere | EHA-EU MCL network guidelines for diagnosis and treatment of MCL |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN15258P | BEMUNAT powder for concentrate for solution for infusion 100 mg/vial | Lyophilised powder for injection |
| SIN15257P | BEMUNAT powder for concentrate for solution for infusion 25 mg/vial | Lyophilised powder for injection |
Both licences are valid single-ingredient products from Natco Pharma Ltd. They are injectable (intravenous) formulations only.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent) |
| Myelosuppression Risk | High (neutropenia, thrombocytopenia and anaemia are expected) |
| Emetogenicity Classification | Moderate |
| Monitoring Items | CBC with differential, liver and renal function, signs of infection |
| Handling Protection | Must follow cytotoxic drug handling regulations |
These entries reflect general knowledge of the drug class, because no drug-specific toxicity data were available. Please refer to the package insert warnings and precautions for authoritative information.
Safety Considerations
- Disease associations flagged in the knowledge graph (not taken from label text): liver failure, liver disease, kidney disease, gallbladder disease, pyoureter, thrombocytopenia, neutropenia, agranulocytosis, anaemia and macrocytic anaemia. These are caution signals that need confirmation against the product label.
- Drug interactions: 100 interacting drugs were identified.
- Major: deferiprone and samarium-153 lexidronam, mainly because of additive effects on blood counts.
- Moderate (examples): omeprazole, esomeprazole, cimetidine, caffeine, mercaptopurine, ticlopidine, chloramphenicol, deferasirox, roflumilast, obeticholic acid and osilodrostat.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: At least three completed Phase 3 randomised trials (including the BRIGHT study, NCT00991211 and the ibrutinib add-on trial) support bendamustine plus rituximab in MCL. Recent guidelines and further Phase 3 trials with BTK inhibitors confirm BR as a standard backbone. The evidence is strong. However, the Singapore registrations carry no indication text, and the safety label data are incomplete.
To proceed, the following is needed:
- Download and review the HSA package insert to confirm approved indications, warnings and contraindications
- Mechanism of action data from DrugBank
- A safety monitoring plan for myelosuppression and infection, with extra attention to patients with liver or kidney impairment
- A check of concomitant medications against the major and moderate interaction list
- Confirmation of whether the current Singapore labelling covers MCL, or whether a new-indication application is required
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.